Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

Ampio reports positive study results on Optina to treat Diabetic Macular Edema Ampio Pharmaceuticals, announced positive results of the OptimEyes trial for DME. The OptimEyes trial was a multiple site, randomized, placebo controlled, parallel, double masked study to evaluate the safety and efficacy of two doses of oral Optina (adjusted to body mass index-BMI) in adult patients with Diabetic Macular Edema (DME).
Contract Research & Services > Clinical Trials > News
Kite Pharma begins dosing in Phase I/II trial of KTE-C19 to treat refractory aggressive NHL By PBR Staff Writer
US-based Kite Pharma has started dosing in its Phase I/II clinical trial of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-Cell therapy, in patients with refractory aggressive Non-Hodgkin's Lymphoma (NHL) has been treated.
Contract Research & Services > Clinical Trials > News Precision Biologics completes patient accrual to ensituximab Phase II colorectal cancer trial Precision Biologics has completed accrual to its Phase 2 study utilizing its novel monoclonal antibody Ensituximab (NPC-1C).
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
GlycoMimetics begins Phase I/II trial of GMI-1271 to treat AML
By PBR Staff Writer
US-based biotechnology firm GlycoMimetics has started dosing in a Phase I/II clinical trial of its new and proprietary E-selectin antagonist, GMI-1271, to treat patients with acute myeloid leukemia (AML).
Contract Research & Services > Clinical Trials > News
Designing Wellness for Fun and Satisfaction: Gummies - Based Nutrition
| By Softigel pbr
The gummy delivery form for vitamins, minerals and supplements is the single-largest source of growth among the supplements category. Vitamin users report preference for gummy/soft chewable products because these offer not only pleasure and a fun experience, but efficacy and convenience. The selection of materials during the design process of the formula is critical for the final product in order to meet the expectations of the consumers, which is to find a healthy product that will give them a delicious reward as well. Based on the design and development process, this paper reviews review in detail the stage of selection of materials and validation as a critical phase to obtain a product that represents quality and stability as well as the specific requirements of the costumers and the consumers.
Contract Research & Services > Clinical Trials > White Papers
AbGenomics begins Phase-Ib/IIa trial of neihulizumab to treat steroid refractory aGvHD
By PBR Staff Writer
US-based biopharmaceutical firm AbGenomics has initiated a Phase-Ib/IIa clinical trial of neihulizumab (AbGn-168H), a humanized monoclonal antibody, for the treatment of steroid refractory acute graft-versus-host disease (aGvHD).
Contract Research & Services > Clinical Trials > News
Alnylam seeks MHRA approval for ALN-AAT Phase I/II trial to treat alpha-1 liver disease
By PBR Staff Writer
US-based Alnylam Pharmaceuticals has filed a Clinical Trial Application (CTA) with the UK Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval to begin a Phase I/II study with ALN-AAT, to treat AAT deficiency-associated liver disease (alpha-1 liver disease).
Contract Research & Services > Clinical Trials > News
Amgen reports positive Phase II trial data for AMG 334 for prevention of episodic migraine
Amgen announced the first results from its global Phase II, double-blind, placebo-controlled study evaluating the efficacy and safety of AMG 334 for the prevention of episodic migraine.
Contract Research & Services > Clinical Trials > News
Adynxx completes enrollment in Phase II trial of AYX1 to prevent post-surgical pain
By PBR Staff Writer
US-based pharmaceutical firm Adynxx has completed patient enrollment in a Phase II dose-ranging clinical trial (ADYX003) of its lead product candidate, AYX1, for prevention of post-surgical pain.
Contract Research & Services > Clinical Trials > News
StemCells reports positive top-line results of thoracic spinal cord injury Phase I/II trial
StemCells (STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases of the central nervous system, announced that Dr Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the Phase I/II study investigating Human Central Nervous System Stem Cell (HuCNS-SC) intramedullary transplantation in thoracic spinal cord injury.
Contract Research & Services > Clinical Trials > News
Takeda to discontinue Phase III trial of alisertib in relapsed or refractory PTCL patients
By PBR Staff Writer
Takeda Pharmaceutical has decided to terminate the Phase III trial of alisertib (MLN8237) for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Contract Research & Services > Clinical Trials > News
Relmada gets notice of allowance for US patent covering Securel technology platform for opioids
Relmada Therapeutics (RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced that Application No. 12/597,702 relating to its proprietary SECUREL abuse deterrent technology platform was allowed for issuance as a new patent by the US Patent and Trademark Office (USPTO).
Contract Research & Services > Clinical Trials > News
Genentech reports positive interim results from Phase II POPLAR study in people with NSCLC
Genentech, a member of the Roche Group, announced interim results from a global, randomized Phase II study (POPLAR) in people with previously treated non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests